The effect of BCECF on intracellular pH of human platelets.

2',7'-Bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein (BCECF) is frequently used for fluorometric determination of intracellular pH (pHi) and its metabolic changes. Studies of BCECF-loaded platelets have reported different pHi values in the range of 6.98 to 7.35, despite the use of the same probe. It is now shown that intracellular BCECF (BCECFi) content affects pHi, and that its over-loading, leads to significantly lower pHi. Different pHi values can be reproduced by changing BCECFi, as reflected by fluorescence intensity. The major loading factors are: the concentration of the probe parent compound, BCECF acetoxymethyl ester (AM), and whether this ester is partly hydrolyzed externally when applied in plasma. When least affected by BCECF, platelet pHi is 7.34. High BCECFi does not affect ATP content, buffer capacity, activation of Na+/H+ exchange by protein kinase C (PKC) and basal PKC activity. On the other hand high BCECFi does inhibit the Na+/H+ exchange rate by over 50%. Since the Na+/H+ exchange strongly affects platelets pHi, it is proposed that this inhibition accounts, at least partly, for the lowered pHi in BCECF over-loaded platelets.

Cyclic AMP-related and cation-affected human platelet chloride transport regulation.

Cystic fibrosis has been characterized as a defect in the regulation of cyclic AMP-dependent transepithelial chloride transport. The activation of cyclic AMP-dependent protein kinase A by cyclic AMP occurs normally in cystic fibrosis cells, but they fail to transport chloride ions in response to protein kinase A stimulation. Defective chloride secretion and abnormal electrolyte transport occurs in several organs including the lung, sweat glands, intestine and pancreas. The present work was aimed at exploring whether the same or similar regulatory systems are functional in platelets, and if they are altered or deficient in individuals with cystic fibrosis. Chloride transport in platelets from normal subjects and from cystic fibrosis patients was measured by cell sizing techniques where chloride permeability is the limiting factor. In platelets from healthy volunteers, the chloride channel blocker, 5-nitro-2-(3-phenylpropylamino) benzoic acid, inhibits the transport in a dose-dependent manner. The preservation of chloride transport capability is shown to be dependent upon the presence of either Ca2+ or two divalent cation substitutes, Cd2+ or Cu2+. It is also shown that in normal subjects 0.1 mumol/l prostaglandin E1, which elevates cyclic AMP 6 times and abolishes platelet aggregation, significantly enhances the rate constant of the transport. Furthermore, in five out of nine cystic fibrosis patients studied, platelet chloride transport did not respond to stimulation by prostaglandin E1.

42 kDa Protein as a Substrate for Protein Phosphatase (s) in Intact Human Blood Platelets.

The level of phosphorylation of any cellular protein depends on the balance of the activities of protein kinases and protein phosphatases that act on the protein. In this study, we have characterized, in intact human blood platelets, the activity of protein phosphatase (s) that reverse the action of protein kinase C (PKC), using as a substrate, endogenous 42 kDa protein which has been previously phosphorylated by PKC. In this study 1,2-dihexanoyl-sn-glycerol (DHG) was used to stimulate PKC, diacylglycerol kinase inhibitor-R59022 was used to maintain the activity of PKC and staurosporine and okadaic acid were used to inhibit PKC and protein phosphatases respectively. Our observations indicate that: (1) protein phosphatase 1 (PP1) and/or protein phosphatase 2A (PP2A) are likely to be the enzymes that reverse the phosphorylation activity of PKC on the 42 kDa protein; (2) PP1 and/or PP2A dephosphorylate sites which have been previously phosphorylated by PKC; and (3) PP1 and/or PP2A dephosphorylate, on the 42 kDa protein, both serine and threonine residues, which have been previously phosphorylated by PKC.

Initiation of RVD response in human platelets: mechanical-biochemical transduction involves pertussis-toxin-sensitive G protein and phospholipase A2.

Platelets revert hypotonic-induced swelling by the process of regulatory volume decrease (RVD). We have recently shown that this process is under the control of endogenous hepoxilin A3. In this work, we investigated the mechanical-biochemical transduction that leads to hepoxilin A3 formation. We demonstrate that this process is mediated by pertussis-toxin-sensitive G protein, which activates Ca(2+)-insensitive phospholipase A2, and the sequential release of arachidonic acid. This conclusion is supported by the following observations: (i) RVD response is blocked selectively by the phospholipase A2 inhibitors manoalide and bromophenacyl-bromide (0.2 and 5 microM, respectively) but not by phospholipase C inhibitors. The addition of arachidonic acid overcame this inhibition; (ii) extracellular Ca2+ depletion by EGTA (up to 10 mM) does not affect RVD; (iii) intracellular Ca2+ depletion by BAPTA-AM (100 microM) inhibits RVD but not hepoxilin A3 formation, as tested by the RVD reconstitution assay; (iv) RVD is inhibited by the G-protein inhibitors, GDP beta S (1 microM) and pertussis toxin (1 ng/ml). This inhibition is overcome by addition of arachidonic acid or hypotonic cell-free eluate that contains hepoxilin A3; (v) NaF, 1 mM, induces hepoxilin A3 formation, tested by the RVD reconstitution assay; and (vii) GDP beta S inhibits hepoxilin A3 formation associated with flow. Therefore, it seems that G proteins are involved in the initial step of the mechanical-biochemical transduction leading to hepoxilin A3 formation in human platelets.

Hepoxilin A3 is the endogenous lipid mediator opposing hypotonic swelling of intact human platelets.

When human blood platelets are exposed to hypotonic medium they swell first but, shortly thereafter, revert toward their original volume in a process termed regulatory volume decrease (RVD). RVD is the result of an enhanced efflux of K+ and Cl- ions and associated water. Platelet RVD is controlled by a short-lived lipoxygenase-derived product (LP). By using a combination of high-performance liquid chromatography, gas chromatography-mass spectrometry, and RVD reconstitution bioassay, we show that LP is identical with hepoxilin A3. In addition we demonstrate that authentic hepoxilin A3 possesses the same biological properties on RVD reconstitution as LP and that the activity of both compounds is amplified through epoxide hydrolase inhibition with 3,3,3-trichloropropene-1,2-oxide. Therefore, we report here that volume expansion causes the formation and release of hepoxilin A3 from intact human platelets and that this hepoxilin plays a major role in volume regulation.

Activation of phospholipase C and protein kinase C has little involvement in ADP-induced primary aggregation of human platelets: effects of diacylglycerols, the diacylglycerols, the diacylglycerol kinase inhibitor R59022, staurosporine and okadaic acid.

The primary phase of ADP-induced aggregation of human platelets does not involve appreciable formation of thromboxane A2 or release of granule contents; lack of formation of inositol trisphosphate has also been noted. Because these responses of platelets to ADP differ so markedly from their responses to other aggregating agents, the roles in ADP-induced aggregation of diacylglycerol, protein kinase C, increases in cytosolic [Ca2+], phosphorylation of pleckstrin (47 kDa) and phosphatases 1 and 2a were investigated. Washed human platelets, prelabelled with [14C]5-hydroxytryptamine and suspended in Tyrode solution (2 mM Ca2+, 1 mM Mg2+), were used for comparisons between the aggregation induced by 2-4 microM ADP, in the presence of fibrinogen, and that induced by 0.05 units/ml thrombin. The diacylglycerol kinase inhibitor 6-(2-[(4-fluorophenyl)phenyl-methylene]-1-piperidinylethyl)-7-meth yl-5H-thiazolo[3,2-a]-pyrimidin-5-one (R59022; 25 microM) had no, or only a slight, enhancing effect on ADP-induced aggregation, but potentiated thrombin-induced responses to a much greater extent. 1,2-Dihexanoyl-sn-glycerol or 1-oleoyl-2-acetyl-sn-glycerol (25 microM) added with or 30-90 s before ADP greatly potentiated aggregation without formation of thromboxane; staurosporine, an inhibitor of protein kinase C, reduced this potentiation. Staurosporine (25 nM) did not inhibit ADP-induced aggregation, although it strongly inhibited thrombin-induced aggregation and release of [14C]5-hydroxytryptamine. All these observations indicate little or no dependence of primary ADP-induced aggregation on the formation of diacylglycerol or on the activation of protein kinase C. At 2-4 microM, ADP did not significantly increase the phosphorylation of pleckstrin (studied with platelets prelabelled with [32P]orthophosphate), but 1,2-dihexanoyl-sn-glycerol- induced phosphorylation of pleckstrin was increased by ADP. Surprisingly, the diacylglycerols strongly inhibited the ADP-induced rise in cytosolic [Ca2+] concurrently with potentiation of ADP-induced aggregation; thus the extent of primary aggregation is independent of the level to which cytosolic [Ca2+] rises. Incubation of platelets with 1,2-dihexanoyl-sn-glycerol or 1-oleoyl-2-acetyl-sn-glycerol for several minutes reversed their potentiating effects on aggregation, and inhibition was observed. Incubation of platelets with okadaic acid, an inhibitor of phosphatases 1 and 2a, inhibited ADP- and thrombin-induced aggregation; although the reason for this effect is unknown, it is unlikely to involve inhibition of phospholipase C, since formation of diacylglycerol appears to have little involvement in the primary phase of ADP-induced aggregation.

Erythrocyte Li+i-Na+o countertransport in the newborn.

The present study investigates the erythrocyte Li+i-Na+o countertransport (CT) in the newborn. Erythrocytes of term infants exhibit no or very low CT activity at birth (0.025 +/- 0.011 mmol Li/l RBC.h). CT rates increase gradually and reach adult values within the 4th-7th day of life (0.225 +/- 0.018 mmol Li/l RBC.h). CT activity in healthy preterm infants at birth is not significantly different from that in term infants (0.014 +/- 0.007 mmol Li/l RBC.h). Postnatal maturation of CT activity in preterm infants is similar to that found in term infants and is independent of gestational age. However, CT rates at birth of premature infants subjected to prenatal stress are significantly higher (0.082 +/- 0.017 mmol Li/l RBC.h). It is concluded that erythrocyte CT activity in the newborn reaches adult values within the first week of life, apparently reflecting the postnatal maturation of the CT system in the cell membrane. We suggest that prenatal stress induces the synthesis of the CT protein in utero.

Protein Kinase C of Human Platelets: Resolution of Ca(2+)-dependent and Independent Forms by Measuring Endogenous Phosphorylation.

This study explores a kinetic approach to distinguish Ca(2+)-dependent and independent forms of PKC activity in a cell-free system of human platelets. Incorporation of (32)P from [γ-(32)P] ATP into total proteins, in the presence or in the absence of histone IIIS, at various combinations of added lipids (diolein and phosphatidyl serine) and Ca(2+), fail to distinguish PKC from other kinases. Phosphorylation of the 40 kDa protein, a major and specific platelet PKC substrate resolved by SDS-PAGE, is completely dependent on the added lipids, allowing the determination of PKC and its two sub-forms: dependent and independent Ca(2+). The activities of these forms and their ratio are characteristics for an individual, while the inter-individual difference is much greater, with an overall average ratio of 2:1 (n = 9). The forms differ in sensitivity to staurosporine with IC(50) = 14.6 and 4.3 nM for the Ca(2+)-dependent and independent forms, respectively. Furthermore, cAMP at 1 µM inhibits selectively the Ca(2+)-dependent form by 45%. Okadaic acid, a potent inhibitor of protein phosphatase 1 and 2A, enhances at 1 µM the activity of the Ca(2+)-dependent form. It is concluded that the two PKC forms that are determined in the crude cell free system of human platelets by measuring the endogenous phosphorylation have distinct properties.

Vasopressin elevation of Na+/H+ exchange is inhibited by genistein in human blood platelets.

The regulation of intracellular Na+ and pHi in human blood platelets is known to be controlled by the function of the Na+/H+ exchanger. The phosphorylation state of the Na+/H+ exchanger which determines the exchanger activity in human blood platelets is regulated by the activities of protein kinases and protein phosphatases. Observations in this study indicate that arginine vasopressin (AVP) that interacts with a V1 receptor, activates the Na+/H+ exchange in human blood platelets through a genistein-inhibited mechanism. The AVP-activated Na+/H+ exchange is probably not regulated by protein kinase C (PKC), since this activation is not inhibited by staurosporine. The multiple ways in which platelet Na+/H+ exchange can be modulated may indicate the critical role played by this exchanger in the homeostasis control of pHi in human blood platelets.

Human platelets exposed to mechanical stresses express a potent lipoxygenase product.

Human platelets exposed to hypotonicity undergo regulatory volume decrease (RVD), controlled by a potent, yet labile, lipoxygenase product (LP). LP is synthesized and excreted during RVD affecting selectively K+ permeability. LP is assayed by its capacity to reconstitute RVD when lipoxygenase is blocked. Centrifugation for preparing washed platelets (1,550 x g, 10 min) is sufficient to express LP activity, with declining potency in repeated centrifugations, indicating that it is not readily replenishable. When platelet suspension flows in a vinyl tubing (1 mm i.d.), at physiological velocity, controlled at 90-254 cm/s, LP formation increases as a function of velocity but declines as result of increasing the tubing length. Stirring the platelets in an aggregometer cuvette for 30 s, yields no LP unless the stirring is intermittent. No associated platelet lysis or aggregation are observed following the mechanical stress applications. These results demonstrate that although mechanical stresses result in LP production, the mode of its application plays a major role. These results may indicate that LP is synthesized under pathological conditions and could be of relevance to platelets behavior related to arterial stenosis.

Effect of synthetic enantiomeric cannabinoids on platelet aggregation.

The effect of a synthetic pair of enantiomeric cannabinoids on platelet function was evaluated. The nonpsychotropic enantiomer, the 1,1-dimethylheptyl homolog of (+)-(3S,4S)-7-hydroxy-delta-6-tetrahydrocannabinol (HU-211), was found to be more active in inhibiting ADP-induced platelet aggregation than the highly psychotropic (-)-enantiomer (HU-210). The related (+)-(3R,4R) cannabinoid, HU-213, which lacks the 7-hydroxy moiety, exerted its inhibitory effect within a wider range of concentrations. The results indicate a differentiation between psychotropic activity and inhibition of platelet aggregation in the cannabinoid group of compounds.

Ligand-affected shift of Na+/H+ exchange pHi set point in human blood platelets, rapidly revealed by a novel approach.

The Na+/H+ exchange time-course of BCECF-loaded human platelets, suspended in isotonic media containing NaCl and sodium propionate and activated by intracellular acidification, was measured spectrofluorimetrically. Sequential alkalinization rates decline exponentially as a function of the changing intracellular pH (pHi) and its linear expression (log rate vs. pHi) extrapolates reproducibly to the pHi set point for the Na+/H+ exchange activation. The set point of control platelets (7.28 +/- 0.01) is shifted rapidly (discernibly less than or equal to 30 s) and markedly to alkaline pHi (7.62 +/- 0.03) by PMA, that activates protein kinase C and is shifted to acidic pHi (7.05 +/- 0.01) by staurosporine, which inhibits protein kinases. The addition of 5-N-(3-aminophenyl)amiloride reveals that the alkalinization measured is predominantly Na+/H+ exchange with only a minute contribution (delta pHi = 0.012 +/- 0.002 in 1 min) of an acid loading component, at pHi greater than 7.2. The results support recent studies concluding that the set point indeed reflects the phosphorylation state of the Na+/H+ exchanger.

Erythrocytes with covalently bound fibrinogen as a cellular replacement for the treatment of thrombocytopenia.

Thrombocytopenia in general, and autoimmune thrombocytopenia in particular, is a disease of high prevalence with a non-satisfactory regime of treatment. The present study aimed to explore the feasibility of an alternative treatment, based on the rationale that autologous erythrocytes modified to bear covalently bound fibrinogen would participate passively in the aggregation of the remaining platelets, thus augmenting the haemostatic needs, while resisting the autoimmune reaction directed towards the platelets. Several procedures for the cross-linking of fibrinogen to red blood cells (RBCs) were tested. Formaldehyde (33 microM) for 10 min at 23 degrees C attached 58 fibrinogen molecules per erythrocyte. These erythrocytes were indistinguishable from untreated erythrocytes in the following properties: osmotic fragility, bound haemoglobin, sedimentation rate, acetylcholinesterase activity, phagocytosis by macrophages, rosette formation with K562 cells. It is shown that RBCs cross-linked with fibrinogen are capable of participating in the in vitro aggregation of platelets and are indeed effective in the in vivo process of arrest of bleeding in an animal model of autoimmune thrombocytopenia.

Higher Na(+)-H+ exchange rate and more alkaline intracellular pH set-point in essential hypertension: effects of protein kinase modulation in platelets.

Na(+)-H+ exchange is known to be elevated in essential hypertension. To examine the mechanism of this elevation, we studied a group of 19 male hypertensive patients (mean age 46 years; systolic/diastolic blood pressure 144/99 mmHg), without medication for at least 2 weeks, and a control group of 19 male normotensives (mean age 49 years; systolic/diastolic blood pressure 118/77 mmHg). Na(+)-H+ exchange and intracellular pH set-point, at which the exchange is approximately nil, were studied spectroflurometrically in blood platelets loaded with 2',7'-bis carboxyethyl-5,6-carboxyfluorescein in an isotonic medium containing 60 mmol/l sodium propionate, pH 7.35. The exchange rate (delta pH per 9 s at intracellular pH 7.0) of hypertensives (0.050 +/- 0.005) is significantly greater (P less than 0.001) than the rate of normotensives (0.027 +/- 0.003), but both groups attain similar high (approximately 0.074) rates when phosphorylation is stimulated by 0.5 mumol/l phorbol 12-myristate 13-acetate (PMA) and similar low rates (approximately 0.01) when inhibited by 0.5 mumol/l staurosporine. Furthermore, although hypertensive set-point is significantly (P less than 0.01) more alkaline (7.33 +/- 0.01) than that of the normotensives (7.27 +/- 0.02), both groups attain a similar set-point in the presence of PMA or staurosporine (approximately 7.62 and approximately 7.08, respectively). It is concluded that more extensive phosphorylation of the exchanger, known to be regulated by phosphorylation, is the reason for the modified properties of Na(+)-H+ exchange in essential hypertension, rather than larger numbers of the exchanger per cell.

Modulation of Na+/H+ exchange and intracellular pH by protein kinase C and protein phosphatase in blood platelets.

Phosphorylation of the Na+/H+ exchanger in human platelets is apparently controlled by the balancing activities of protein kinase C (PKC) and protein phosphatase (PP). To explore cellular expressions of these activities, we have examined the impact of modulation of PKC and PP on Na+/H+ exchange activity, its pHi set point and intracellular pH (pHi). These parameters were followed spectrofluorimetrically in BCECF-loaded platelets. Phorbol 12-myristate 13-acetate (PMA) and dihexanoylglycerol (DHG), which stimulate PKC, and okadaic acid, which inhibits PP 1 and 2A, elevate the measured parameters in concert, while staurosporine, which inhibits protein kinases, had opposite effects. The stimulatory and inhibitory effects are similarly very rapid, being discerned within seconds. It is concluded that: (a) phosphorylation of the Na+/H+ exchanger is the common origin of the diverse effects of PMA, DHG, okadaic acid and staurosporine, (b) Na+/H+ exchange properties are tightly regulated by phosphorylation and dephosphorylation, and (c) the exchanger plays a major role in pHi regulation in platelets.

The Na+/H+ exchanger is phosphorylated in human platelets in response to activating agents.

alpha-Thrombin, phorbol esters (PMA) and 1,2-diacylglycerol (DAG), three activators of the amiloride-sensitive Na+/H+ exchange in human platelets, rapidly increase the intracellular pH and the level of phosphorylation of the Na+/H+ exchange protein (NHE1). This stimulatory effect is suppressed by staurosporine, a potent kinase inhibitor, and increased by okadaic acid, a potent inhibitor of phosphatase 1 and 2A. The modulations of NHE1 phosphorylation by these factors correlate well with their effects on platelet pH. Thus, we conclude that in platelets (i) Na+/H+ exchange is mediated by NHE1, and (ii) platelet activating agents stimulate NHE1 via the modulation of the kinase/phosphatase equilibrium.

Lipoxygenase product controls the regulatory volume decrease of human platelets.

SUMMARY. Blood platelets exposed to hypotonic medium are known to undergo a regulatory volume decrease (RVD), mediated by increased conductive permeability of K(+) and Cl(-). It is presently shown that RVD in platelets is controlled by a lipoxygenase product, apparently by a selective regulation of K(+) permeability. This conclusion is supported by the following observations: (a) lipoxygenase inhibitors, nordihydroguaiaretic acid (NDGA), N-(3-phenoxycinnamyl)-acetohydroxamic acid (BW A4C), methyl 2-[(3,4-dihydro-3,4-dioxo-naphthalenyl)amino]-benzoate (CGS 8515), and 5,8,11,14-eicosatetraynoic acid, inhibit RVD with IC(50) values of 3,6,10, and 5 µM, respectively. In contrast, aspirin and indomethacin, known cycloxygenase inhibitors, are innocuous; (b) an eluate from platelets undergoing RVD restores RVD in NDGA-treated platelets; (c) the eluate is unstable (t(1/2) = 8 s and 2 min in the presence and absence of platelets, respectively); furthermore, albumin promotes platelet RVD; (d) known lipoxygenase products, 12-hydroperoxyeicosatetraenoic acid, 12-hydroxyeicosatetraenoic acid and leukotriene D(4), restore RVD in NDGA-treated platelets at 0.1-1.0 µM; (e) the extended hypotonic swelling of gramicidin-treated platelets, expressing Cl(-) permeability, is insensitive to NDGA. It is hypothesized that the lipoxygenase product selectively opens K(+) channels in platelets, in analogy with the effect of lipoxygenase products in cardiac atrial cells and Aplysia sensory neurons.